Under the terms of the clinical supply agreement, Immuneering will sponsor the planned studies and Regeneron will provide Libtayo. Immuneering will maintain global development and ...

in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer (NSCLC) in its ongoing Phase 2a study. IMM-1-104 is currently in a Phase 1/2a study ...

Under the terms of the clinical supply agreement, Immuneering will sponsor the planned studies and Regeneron will provide Libtayo. Immuneering will maintain global development and commercialization ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

A Columbus woman has been charged with murder after police say she shot and killed her ex-boyfriend at a Worthington apartment complex parking lot during a possible domestic violence-related incident.

Dupixent and Libtayo should be enough to offset Eylea franchise erosion and drive low to mid-single digit topline growth in 2025. 2025 should be a trough year for Regeneron's top and bottom line ...

Drawing any comparisons between studies is always a challenge, and the bottom line is that Libtayo/chemo joins a select group of PD-1/PD-L1 drugs that have shown efficacy in first-line NSCLC.

A shooting in the Columbus suburb of New Albany has left one person dead and five wounded. Authorities apprehended the suspect in Columbus Wednesday morning. It's the first mass shooting of 2025 ...